The therapeutic off‐target effects of ibrutinib studied until now in the haematopoietic system mainly relate to its activity as an ITK inhibitor, which affects helper T cells differentiation, thereby influencing the immune response against tumours and infections, but also potentially harness other immune functions. This evidence concerns the gene ITK and neoplasm.